Verona PharmaVRNA
About: Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. The company is currently focusing on developing its Ensifentrine product candidate, which will treat chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and other respiratory diseases, including asthma.
Employees: 79
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
142% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 19
102% more capital invested
Capital invested by funds: $965M [Q2] → $1.94B (+$979M) [Q3]
57% more funds holding in top 10
Funds holding in top 10: 7 [Q2] → 11 (+4) [Q3]
21% more funds holding
Funds holding: 123 [Q2] → 149 (+26) [Q3]
0% less call options, than puts
Call options by funds: $27.5M | Put options by funds: $27.6M
0.73% less ownership
Funds ownership: 11.11% [Q2] → 10.38% (-0.73%) [Q3]
11% less repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 46
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
4 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 144 / 330 met price target | 2%upside $60 | Buy Reiterated | 21 Jan 2025 |
Roth MKM Boobalan Pachaiyappan 63% 1-year accuracy 5 / 8 met price target | 16%upside $68 | Buy Initiated | 10 Jan 2025 |
Wells Fargo Tiago Fauth 57% 1-year accuracy 13 / 23 met price target | 26%upside $74 | Overweight Maintained | 8 Jan 2025 |
Truist Securities Joon Lee 53% 1-year accuracy 23 / 43 met price target | 3%downside $57 | Buy Reiterated | 8 Jan 2025 |
Financial journalist opinion
Based on 3 articles about VRNA published over the past 30 days









